ReutersEU drugs regulator to allow Novo Nordisk to include heart condition in Ozempic label14 hours agoMore
HealioSemaglutide may improve stroke risk vs. empagliflozin for diabetes19 hours agoBy Scott BuzbyMore
Pharmacy TimesADA 2025: Oral Semaglutide Demonstrates Cardiovascular Benefits in SOUL TrialYesterdayBy Kennedy FerruggiaMore
HCPLiveSTRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes3 days agoBy Patrick CampbellMore
PR NewswireOral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes2 days agoMore
WV NewsSemaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes3 days agoMore
MarketScreenerCHMP Recommends Update for Ozempic Following Positive Stride Study Results4 hours agoMore
Pharmacy TimesADA 2025: Semaglutide Shows Promise in Improving Mobility for Patients With Diabetes and Peripheral Arterial Disease2 days agoBy Kennedy FerruggiaMore
Full coverageFull coverage